AbbVie Inc to Post Q1 2018 Earnings of $1.56 Per Share, Leerink Swann Forecasts (NYSE:ABBV)

AbbVie Inc (NYSE:ABBV) – Leerink Swann issued their Q1 2018 earnings estimates for AbbVie in a research report issued to clients and investors on Tuesday, Zacks Investment Research reports. Leerink Swann analyst G. Porges expects that the company will post earnings of $1.56 per share for the quarter. Leerink Swann currently has a “Buy” rating and a $106.00 target price on the stock. Leerink Swann also issued estimates for AbbVie’s Q4 2018 earnings at $1.89 EPS.

Other research analysts have also recently issued reports about the stock. SunTrust Banks reissued a “buy” rating and issued a $95.00 price objective on shares of AbbVie in a research note on Wednesday, September 13th. UBS Group cut shares of AbbVie from a “buy” rating to a “neutral” rating and lifted their price objective for the company from $79.00 to $92.00 in a research note on Monday, September 25th. Argus lifted their price objective on shares of AbbVie from $90.00 to $110.00 and gave the company a “buy” rating in a research note on Friday, September 29th. Barclays reissued a “hold” rating and issued a $68.00 price objective on shares of AbbVie in a research note on Thursday, September 28th. Finally, Jefferies Group reaffirmed a “buy” rating and set a $107.00 target price on shares of AbbVie in a research note on Thursday, September 28th. Seven investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $100.26.

Shares of AbbVie (NYSE:ABBV) traded down $1.08 during trading hours on Wednesday, reaching $96.71. 3,213,870 shares of the company were exchanged, compared to its average volume of 4,128,349. The company has a market capitalization of $156,114.89, a PE ratio of 23.53, a price-to-earnings-growth ratio of 1.36 and a beta of 1.52. The company has a debt-to-equity ratio of 5.08, a current ratio of 1.45 and a quick ratio of 1.32. AbbVie has a fifty-two week low of $59.27 and a fifty-two week high of $99.10.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 27th. The company reported $1.41 earnings per share for the quarter, beating analysts’ consensus estimates of $1.39 by $0.02. The company had revenue of $7 billion during the quarter, compared to the consensus estimate of $7 billion. AbbVie had a net margin of 24.38% and a return on equity of 153.80%. The firm’s quarterly revenue was up 8.8% on a year-over-year basis. During the same period in the previous year, the business earned $1.21 earnings per share.

The business also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be paid a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.94%. The ex-dividend date of this dividend is Thursday, January 11th. This is a boost from AbbVie’s previous quarterly dividend of $0.64. AbbVie’s payout ratio is presently 62.29%.

In related news, Chairman Richard A. Gonzalez sold 218,193 shares of the business’s stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $94.01, for a total value of $20,512,323.93. Following the sale, the chairman now owns 492,030 shares of the company’s stock, valued at $46,255,740.30. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Timothy J. Richmond sold 87,040 shares of the business’s stock in a transaction on Monday, December 18th. The stock was sold at an average price of $98.45, for a total transaction of $8,569,088.00. Following the completion of the sale, the senior vice president now directly owns 113,118 shares in the company, valued at approximately $11,136,467.10. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 494,676 shares of company stock worth $47,237,938. Insiders own 0.23% of the company’s stock.

Several institutional investors have recently modified their holdings of the stock. Parametric Portfolio Associates LLC lifted its holdings in AbbVie by 5.8% in the third quarter. Parametric Portfolio Associates LLC now owns 3,418,955 shares of the company’s stock valued at $303,808,000 after buying an additional 188,933 shares during the period. Shelton Capital Management lifted its holdings in AbbVie by 59.6% in the third quarter. Shelton Capital Management now owns 127,799 shares of the company’s stock valued at $11,356,000 after buying an additional 47,700 shares during the period. GSB Wealth Management LLC acquired a new position in AbbVie in the third quarter valued at $240,000. Steward Partners Investment Advisory LLC acquired a new position in AbbVie in the third quarter valued at $5,754,000. Finally, Public Employees Retirement System of Ohio lifted its holdings in AbbVie by 0.4% in the third quarter. Public Employees Retirement System of Ohio now owns 1,101,377 shares of the company’s stock valued at $97,868,000 after buying an additional 4,028 shares during the period. 69.18% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This story was first posted by Week Herald and is owned by of Week Herald. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://weekherald.com/2017/12/30/leerink-swann-weighs-in-on-abbvie-inc-s-q1-2018-earnings-abbv.html.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Get a free copy of the Zacks research report on AbbVie (ABBV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply